![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
STORM Therapeutics Expands R&D Leadership Team
Matthew Fyfe joins as Senior Vice President of Therapeutics
…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Novo Holdings participates in portfolio company Amolyt Pharma’s $138 million financing
Amolyt is developing therapeutic peptides for rare endocrine…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Novo Holdings invests in proteomics technology company, Evosep
COPENHAGEN, DENMARK — Novo Holdings, a leading international…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Positive Initial Data Analysis in POLB 001 LPS Challenge Trial
Early data read out indicates a successful LPS human challenge…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs
AMSTERDAM, THE NETHERLANDS, 5 January 2023 — Synaffix B.V.,…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
IOnctura Provides Development Update On First-In-Class Semi-Allosteric PI3Kδ Inhibitor Program
Updated clinical data demonstrates a prolonged and sustained…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine
Newly appointed CMO with more than 25 years’ experience…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform
Adcendo licenses Duality’s DITAC (Duality Immune Toxin…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program
Amsterdam and San Francisco / Houston / Singapore, 4 January…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma
─Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme
Collaboration with OneThree Biotech identifies novel RSV treatments
First…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
IOnctura Awarded EUR17.5 Million Funding From The EIC Accelerator For Clinical Development Of Novel Pancreatic Cancer Therapy
Funding will support iOnctura’s clinical program for IOA-289,…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
Statistically significant improvements in lung function, symptoms…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
2022 | Optimum’s Year in Review
It’s nearly the end of 2022! It was an exciting year for Optimum’s…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Cutting-edge protein design project to join BioInnovation Institute’s Bio Studio program
BioInnovation Institute (BII), an international enterprise foundation…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus
Financing from new investors Trill Impact Ventures and Pureos…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Alchemab Therapeutics | The Chain Podcast
THE CHAIN PODCAST
Our Co-Founder and CSO Jane Osbourn was delighted…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Biocomposites announce a year of record sales and company growth
Winner of two Queen’s Awards for Enterprise in Innovation…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
ImaginAb Launches Phase II C-IT Neo Trial using CD8+ Cell Imaging to Investigate Neoadjuvant Immunotherapy
Los Angeles, USA and New York, USA, December 14, 2022 – ImaginAb…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York